June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Genetic Interaction with Response to Oral Micronutrient Supplements in the Age-Related Eye Disease Study 2 (AREDS2)
Author Affiliations & Notes
  • Emily Chew
    Epidemiology & Clinical Applications, National Eye Institute, Bethesda, Maryland, United States
  • Chi-Yang Chiu
    National Institute of Child Health and Human Development, Bethesda, Maryland, United States
  • Elvira Agron
    Epidemiology & Clinical Applications, National Eye Institute, Bethesda, Maryland, United States
  • Traci E Clemons
    EMMES Corporation, Rockville, Maryland, United States
  • Freekje van Asten
    Epidemiology & Clinical Applications, National Eye Institute, Bethesda, Maryland, United States
  • Ruzong Fan
    Georgetown University, Washington, District of Columbia, United States
  • Footnotes
    Commercial Relationships   Emily Chew, None; Chi-Yang Chiu, None; Elvira Agron, None; Traci Clemons, None; Freekje van Asten, None; Ruzong Fan, None
  • Footnotes
    Support  Contract No. HHS-N-260-2005-00007-C. ADB Contract No. N01-EY-5-0007.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2985. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Emily Chew, Chi-Yang Chiu, Elvira Agron, Traci E Clemons, Freekje van Asten, Ruzong Fan; Genetic Interaction with Response to Oral Micronutrient Supplements in the Age-Related Eye Disease Study 2 (AREDS2). Invest. Ophthalmol. Vis. Sci. 2017;58(8):2985.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess whether genotypes at two major loci associated with age-related macular degeneration (AMD), complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS) interact with the response to oral nutrients for the treatment of AMD in a clinical trial, the Age-Related Eye Disease Study 2 (AREDS2).

Methods : AREDS2 participants (n=4203) who had bilateral intermediate AMD (large drusen) or late AMD in 1 eye were randomly assigned to lutein/zeaxanthin, omega-3 fatty acids (DHA and EPA), low or high doses of zinc (25 mg vs. 80 mg). At baseline and annual study visits, history of treatment for late AMD and fundus photographs were obtained to evaluate for progression to late AMD. The outcome was late AMD, which was further evaluated for either geographic atrophy (GA) or neovascular AMD. Mixed effect Cox regression models using both eyes were conducted adjusting for age, sex, education level, and smoking history.

Results : 1732 participants had complete data including the genetic information. SNPs rs1061170 in the CFH gene and rs10490924 in the ARMS2 gene were evaluated. The participants (median age (SE): 72.5 y (7.8), 58.8% female, 97.1% white) were followed for a median of 6.5 years. These genetic variants in CFH and ARMS2 were found to increase the risk of progression. The test of interaction for each of the treatments with lutein and zeaxanthin, omega3-fatty acids, and varying dosage of zinc show no statistically significant interaction of the SNPs on the response to the oral supplements (see Table).

Conclusions : There was no interaction of the response to any of the nutrient supplements with the known genetic SNPs that are associated with increased risk of progression to late AMD, including GA and neovascular AMD in AREDS2. Because only approximately half of our participants had genetic testing we may be limited in our power to truly evaluate for interaction. However, previous studies of genetic interactions in the first AREDS found that there were similar responses to the nutrient supplements, regardless of genetic factors.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×